EICHOR
● Not Yet Recruiting
Efficacy and Safety of Guselkumab in Patients With Moderate-to-Severe Ulcerative Colitis:A Real-World Prospective Cohort Study.
Condition: Ulcerative Colitis (Disorder) · Guselkumab · Sponsor: Second Affiliated Hospital of Wenzhou Medical University
About this study
In a real-world setting, this study systematically evaluates the clinical efficacy and safety of guselkumab (GUS) in the treatment of ulcerative colitis (UC), encompassing multi-dimensional outcomes including clinical remission, biochemical remission, endoscopic remission, histologic healing, and intestinal ultrasound changes.
This description comes directly from the study's public registry record.
Talk to the study team
Yi Jiang, Doctor of Medicine · +8613676715542 · wzjiangyi@yeah.net
guolong Ma, Master of Medicine · 15868508303 · maguolong2014@163.com
Always discuss trial participation with your own doctor first.
Locations (1)
| The Second Affiliated Hospital of Wenzhou Medical University | Wenzhou, Zhejiang, China | — |
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07726888